Voir la source de 4 Estimates On Volasertib This Summer

LDL-C was directly measured. Lipid and lipoprotein levels were obtained at baseline and at 8 weeks treatment. PON1 activity of the serum samples was measured using full automated paraoxonase activity measurement kit (Mega Tip, Gaziantep, Turkey) on Hitachi 7600 automatic biochemical analyzer (Hitachi, Tokyo, Japan).11) [https://en.wikipedia.org/wiki/Ritipenem Ritipenem] Statistical analysis All measurements were represented as mean��standard deviation or absolute number (percentage). The patients were divided into two groups according to the changes in HDL-C: increased HDL group [on-treatment HDL-C��baseline HDL-C], and decreased HDL group [on-treatment HDL-C LDL-C levels were 65.5��23.4 mg/dL. Rosuvastatin treatment increased the mean HDL-C concentration by 1.9��9.2 mg/dL (6.4��21.4%). HDL-C levels increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. The baseline clinical characteristics according to HDL-C response are shown in Table 1. There was no significant difference [http://www.selleckchem.com/products/BI6727-Volasertib.html Volasertib solubility dmso] in the most relevant clinical characteristics between the two groups. Table 1 Baseline clinical characteristics Changes of lipid and lipoprotein Total cholesterol, triglyceride and LDL-C levels decreased after statin treatment [http://www.selleckchem.com/products/cb-839.html selleck chemical] (Table 2). Baseline HDL-C levels were higher in patients with decreased HDL-C at 8 weeks (47.4��10.0 vs. 42.1��9.1 mg/dL, p